 Ritonavir, a peptidomimetic HIV protease inhibitor, was marketed in 1996.It was designed to fit the C2-symmetry in the binding site of the protease.The developers of ritonavir, Abbott Laboratories, started with compounds that were active against the virus but had poor bioavailability.